Skip to main content
Fig. 3 | Molecular Cancer

Fig. 3

From: RETRACTED ARTICLE: Exosome-transmitted miR-128-3p increase chemosensitivity of oxaliplatin-resistant colorectal cancer

Fig. 3

Expression level of miR-128-3p is correlate with oxaliplatin treatment response in CRC patients. a RT-qPCR analysis of miR-128-3p in CRC tissues from healthy donors (HD, n = 20) and patients who were therapy naive (Untreated, n = 18), benefited from neoadjuvant oxaliplatin therapy (Neoadjuvant, n = 18) and relapsed during oxaliplatin therapy (Post-relapse, n = 15). b RT-qPCR analysis of miR-128-3p in the pre-therapy tissue of CRC patients with non-PD (n = 35) or PD (n = 40) during oxaliplatin therapy. c ROC curves for detection of oxaliplatin using miR-128-3p as assessed by AUC. Kaplan–Meier survival curves analysis of PFS in CRC patients with or without oxaliplatin therapy. d All patients (n = 122); e. Patients with low miR-128-3p expression (n = 61); f. Patients with high miR-128-3p expression (n = 61). The median value of miR-128-3p expression level was used as a cut-off. Results are presented as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001

Back to article page